Tango Therapeutics nets $60m Series B

Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this